Ensuring success in AAV scale-up: key data from case studies across four serotypes (APAC)

Thursday 08:30 IST / 11:00 AWST / 12:00 KST / 12:00 JST / 13:00 AEST / 15:00 NZST

Sponsor

Ensuring success in AAV scale-up: key data from case studies across four serotypes (APAC)

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Explore key considerations and best practices for scaling AAV production, including selecting a transient transfection cell line and scale-up strategies for rAAV processes.

Data from small-scale case studies across four AAV serotypes will be explored, demonstrating:

scale-up of an rAAV9 process at 50 L and 200 L scale with yields of ≥ 2 × 10¹¹ vg/mL
low hcDNA (including encapsidated)
post-affinity chromatography yields of < 18 ng/10¹⁴ vg.

Leave with a roadmap for process scale-up in single-use bioreactor systems along with insights into choosing the best tools and cell lines for your application and serotype.

Attend this webinar to:

Gain knowledge of rAAV production process development
Learn how to best approach process scale-up
Understand why cell line selection is key to success

Kelly Cybulski

Senior Scientist, R&D at Cytiva

Kelly Cybulski is a Senior Scientist in R&D at Cytiva, where she has spent the past six years advancing viral vector process and product development. With a Master’s degree in Cell and Molecular Biology from the University of Rhode Island and 19 years of experience spanning GMP (Good Manufacturing Practice) production, process development, and research, Kelly brings deep technical expertise and a proven track record of innovation in biopharmaceutical manufacturing.

Kyle Burrell

Upstream Field Application Specialist at Cytiva

Kyle joined Cytiva in 2022 as a Bioreactor Application Specialist, bringing with him a strong background in bioreactor scale-up and process development. In 2023, he became part of the Genomic Medicine Operating Company, where he now focuses on viral vector technologies. Prior to joining Cytiva, Kyle worked in assay and analytical development for viral vectors. He holds a Master’s degree in Veterinary Medical Sciences from the University of Calgary, with a specialization in Comparative Biology, Experimental Medicine, and Stem Cell research.

Andrew Low (Joining for Q&A)

Genomic Medicine FAS Leader, APAC at Cytiva

Dr. Andrew Low is an accomplished scientist and industry leader with over 15 years of experience in the development and manufacturing of human therapeutics. With more than 12 years driving innovative R&D initiatives across oncology and infectious diseases, he is a recognized subject matter expert in biologics and advanced therapy medicinal products (ATMPs).

Andrew has a strong track record in process development (PD), having formulated over 70 cell culture basal media and more than 40 nutrient feeds. His expertise has supported successful process scale-up from early research through to clinical and commercial manufacturing. Currently, he leads a team of FAS across APAC at Danaher-Cytiva, providing end-to-end support for gene therapy, cell therapy, nucleic acid therapeutics, and nanomedicines. He works cross-functionally with commercial, R&D, quality, product management, and manufacturing teams, while also serving as industry thought leadership as speaker and panelist at international conferences.

Prior to joining Danaher-Cytiva, Andrew held leadership roles at Thermo Fisher Scientific and CSL Ltd, where he drove bioprocessing innovations in cell culture media and upstream PD for recombinant proteins and monoclonal antibodies.

Andrew holds a Ph. D and BSc (Hons) from Murdoch University and had his early career as a postdoctoral research fellow at The Walter and Eliza Hall Institute of Medical Research, focusing on cancer and infectious diseases. His scientific contributions include patent and publications in international journals.

You have registered for this webinar